Saturday 17 October 2026 Export EXEL’s income statement to Excel — free account

Exelixis, Inc.

Exelixis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 6.98% from fiscal 2024. In the quarter to June 2026, revenue grew 10.6%, EPS grew 25.0% and free cash flow grew 557.3%, each against the same quarter a year earlier. Revenue growth for ten consecutive years; insiders bought in the last twelve months.

62.11 0.72 −1.15%

Follow EXEL

Alert me

Market cap: $15.6B
P/E: 18.8×
Fwd P/E: 16.7×
Dividend yield: —
F-score: 7/9
Altman Z: 12.68
Beneish M: −2.61
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Exelixis, Inc. (EXEL) P/E ratio

Alert me on P/E ratio

As of 16 October 2026, Exelixis, Inc. (EXEL) trades at a P/E ratio of 18.8×. Over the past ten years it has ranged from 0.0× (June 2017) to 146× (August 2017); the current reading is higher than 51% of that period. That is above the Biotechnology industry median of 8.5× and below the Healthcare sector median of 23.0×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/EXEL/pe-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Exelixis, Inc. P/E ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/EXEL/metrics/pe-ratio">Exelixis, Inc. (EXEL) P/E ratio — stockrow.com</a></p>

Period	P/E ratio	Change
FY2025	15.2×	(18.02%)
FY2024	18.5×	(49.49%)
FY2023	36.6×	28.09%
FY2022	28.6×	15.00%
FY2021	24.9×	(54.16%)
FY2020	54.2×	226.32%
FY2019	16.6×	94.37%
FY2018	8.6×	(85.56%)
FY2017	59.2×	—
FY2016	0.0×	—

Period	P/E ratio	Change
Jun 2026	16.5×	20.32%
Mar 2026	13.7×	(9.65%)
Dec 2025	15.2×	(9.66%)
Sep 2025	16.8×	(18.11%)
42 more quarters	Free account

Against its own ten years

Low 0.0× High 146×

Ten-year median 18.7×

Current reading's percentile 37

Company	P/E ratio
SMMT Summit Therapeutics PLC compare	n/m
BBIO BridgeBio Pharma, Inc. compare	n/m
INSM Insmed, Inc. compare	n/m
JAZZ Jazz Pharmaceuticals PLC compare	13.8×
ASND Ascendis Pharma A/S compare	16.3×
EXEL Exelixis, Inc.	18.8×
HALO Halozyme Therapeutics, Inc. compare	34.6×
TECH Bio-Techne Corp compare	62.0×
CORT Corcept Therapeutics Incorporated compare	212×
Biotechnology industry median	8.5×
Healthcare sector median	23.0×
Market median	18.1×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

Exelixis, Inc. (EXEL) P/E ratio

P/E ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/E ratio against peers

What P/E ratio is

More on EXEL

P/E ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/E ratio against peers

What P/E ratio is

More on EXEL

Stockrow Weekly